This appears applicable in both germinal center cell and activated B cell-derived DLBCL and may justify the evaluation of a combined PI3Kβ/δ and mTOR inhibition in clinical trials [94]. This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.